Singletto Inc. — SEC Form D Filing

Singletto Inc. filed an SEC Form D on March 5, 2026, reporting $100K raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
March 5, 2026
Amount reported
$100K
Round stage
Seed
Industry
Health Care
Website
https://www.singletto.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: WASHINGTON

Problem

Existing antimicrobial technologies have been unable to support the demand for effective products in critical environments.

Solution

Singletto's Oxafence technology integrates antimicrobial performance directly into materials, enabling new product categories that meet unmet needs.

Why now

The need for effective antimicrobial solutions has intensified due to recent global health challenges.

Verdict

Investors said yes at this moment because Singletto's narrative tied directly to an accelerating demand for effective antimicrobial solutions amid global health concerns, not merely because of a novel technology. They were betting on the integration of antimicrobial performance into materials addressing critical market gaps, which implied a potential shift in product development across various healthcare settings. However, limited upside comes from the risk of commoditization of antimicrobial technologies, as passive strategies may quickly evolve to meet demand without significantly differentiating from competitors.

Source: SEC EDGAR Form D filing